| |

Pleural Mesothelioma Staging: These Overlooked Lymph Nodes Might Help

pleural mesothelioma staging

An often-ignored set of lymph nodes behind the ribs could help make pleural mesothelioma staging more accurate and valuable. 

Staging is the process of determining how advanced a patient’s cancer is. It involves looking at various different factors and assigning a rating between 0 and 4. A higher stage indicates more extensive cancer.

A new report suggests that the posterior intercostal lymph nodes behind the ribs play a more important role in pleural mesothelioma staging than previously thought. Mesothelioma patients with cancer in these nodes lived half as long as other mesothelioma patients. 

Researchers in Maryland and Pennsylvania say removing and examining these nodes may lead to more accurate staging, more informed treatment decisions, and better outcomes.  

How Lymph Nodes are Involved in Cancer Staging

Lymph nodes are small bean-shaped structures found throughout the body. They are part of the immune system. 

The job of the lymph nodes is to filter substances that travel through the lymphatic fluid. In people with cancer, this can include cancer cells. Removing and examining lymph nodes for signs of mesothelioma can help doctors determine how far the cancer has spread.

Different parts of the body drain into different sets of lymph nodes. When a surgeon performs cancer surgery, he typically also removes the lymph nodes that are most likely to be affected. These lymph nodes are then used in pleural mesothelioma staging.  

The Role of Intercostal Lymph Nodes in Pleural Mesothelioma Staging

Pleural mesothelioma is a fast-growing cancer associated with asbestos exposure. It starts on the membrane around the lungs. 

Lymphatic fluid in this space drains into a set of lymph nodes in the center of the chest directly behind the heads of the ribs. These are the posterior intercostal lymph nodes. 

These lymph nodes are not usually part of pleural mesothelioma staging. But cancer research at the University of Pennsylvania and the University of Maryland suggests that they probably should be. 

Nodes Could Help Direct Mesothelioma Treatment

Researchers removed and tested the posterior intercostal lymph nodes in 56 consecutive mesothelioma surgery patients. They found that when these particular lymph nodes were involved, the patient’s prognosis was “significantly poorer”.

This was true even in patients with the same cancer stage. Overall, study subjects with Stage 2 mesothelioma lived for more than 26 months. But the Stage 2 patients with positive posterior intercostal lymph nodes died at a median of just 14.4 months. 

Nearly half of the mesothelioma patients tested had cancer cells in their posterior intercostal lymph nodes. In 11 percent of patients, these were the only lymph nodes involved. 

“This first reported series of posterior intercostal lymph nodes revealed they independently more than doubled the risk of progression and death,” concludes lead researcher Joseph Friedberg, MD.

Dr. Friedberg and his colleagues say these nodes should be studied further for their potential in pleural mesothelioma staging. They hope to find ways to test them without doing surgery which could make them more useful for mesothelioma treatment planning

Source:

Friedberg, JS, et al, “This first reported series of posterior intercostal lymph nodes revealed they independently more than doubled the risk of progression and death”, October 18, 2019, Annals of Thoracic Surgery, Epub ahead of print, https://www.annalsthoracicsurgery.org/article/S0003-4975(19)31588-7/pdf

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…